

# Characterisation and outcomes of ARDS secondary to pneumonia in patients with and without SARS-CoV-2: a single-centre experience

Rahul Y Mahida ,<sup>1</sup> Minesh Chotalia,<sup>1,2</sup> Joseph Alderman,<sup>1,2</sup> Chhaya Patel,<sup>3</sup> Amber Hayden,<sup>4</sup> Ruchi Desai,<sup>4</sup> Emily Beesley,<sup>4</sup> Louise E Crowley,<sup>1</sup> Marina Soltan,<sup>1</sup> Mansoor Bangash,<sup>1,2</sup> Dhruv Parekh ,<sup>1,2</sup> Jaimin Patel,<sup>1,2</sup> David R Thickett<sup>1</sup>

**To cite:** Mahida RY, Chotalia M, Alderman J, *et al.* Characterisation and outcomes of ARDS secondary to pneumonia in patients with and without SARS-CoV-2: a single-centre experience. *BMJ Open Resp Res* 2020;**7**:e000731. doi:10.1136/bmjresp-2020-000731

► Additional material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjresp-2020-000731>).

RYM and MC are joint first authors.

Received 30 July 2020  
Revised 15 October 2020  
Accepted 19 October 2020



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

**Correspondence to**  
Dr Rahul Y Mahida;  
[r.mahida@bham.ac.uk](mailto:r.mahida@bham.ac.uk)

## ABSTRACT

**Introduction** Acute respiratory distress syndrome (ARDS) is the major cause of mortality in patients with SARS-CoV-2 pneumonia. It appears that development of ‘cytokine storm’ in patients with SARS-CoV-2 pneumonia precipitates progression to ARDS. However, severity scores on admission do not predict severity or mortality in patients with SARS-CoV-2 pneumonia. Our objective was to determine whether patients with SARS-CoV-2 ARDS are clinically distinct, therefore requiring alternative management strategies, compared with other patients with ARDS. We report a single-centre retrospective study comparing the characteristics and outcomes of patients with ARDS with and without SARS-CoV-2.

**Methods** Two intensive care unit (ICU) cohorts of patients at the Queen Elizabeth Hospital Birmingham were analysed: SARS-CoV-2 patients admitted between 11 March and 21 April 2020 and all patients with community-acquired pneumonia (CAP) from bacterial or viral infection who developed ARDS between 1 January 2017 and 1 November 2019. All data were routinely collected on the hospital’s electronic patient records.

**Results** A greater proportion of SARS-CoV-2 patients were from an Asian ethnic group ( $p=0.002$ ). SARS-CoV-2 patients had lower circulating leucocytes, neutrophils and monocytes ( $p<0.0001$ ), but higher CRP ( $p=0.016$ ) on ICU admission. SARS-CoV-2 patients required a longer duration of mechanical ventilation ( $p=0.01$ ), but had lower vasopressor requirements ( $p=0.016$ ).

**Discussion** The clinical syndromes and respiratory mechanics of SARS-CoV-2 and CAP-ARDS are broadly similar. However, SARS-CoV-2 patients initially have a lower requirement for vasopressor support, fewer circulating leukocytes and require prolonged ventilation support. Further studies are required to determine whether the dysregulated inflammation observed in SARS-CoV-2 ARDS may contribute to the increased duration of respiratory failure.

## INTRODUCTION

SARS-CoV-2 pneumonia can progress to hypoxaemic respiratory failure requiring mechanical ventilation, with patients

## Key messages

- This is the first UK study comparing the clinical characteristics and outcomes of acute respiratory distress syndrome (ARDS) secondary to pneumonia in patients with and without SARS-CoV-2.
- Are patients with SARS-CoV-2 ARDS clinically distinct to other patients with ARDS, therefore, requiring alternative management strategies?
- While the clinical syndromes of ARDS secondary to SARS-CoV-2 and community-acquired pneumonia are similar, SARS-CoV-2 patients initially have a lower requirement for vasopressor support and require prolonged ventilation support.

fulfilling the Berlin criteria for acute respiratory distress syndrome (ARDS).<sup>1–3</sup> Intensive care unit (ICU) mortality rates of up to 68% from SARS-CoV-2 ARDS have been reported.<sup>3,4</sup> A multinational study undertaken prior to the SARS-CoV-2 pandemic found that pneumonia was the underlying risk factor in 59% of ARDS cases.<sup>5</sup> Recently, a retrospective cohort study undertaken in Wuhan, China found that 41.8% of adult patients admitted with SARS-CoV-2 pneumonia developed ARDS.<sup>6</sup> Risk factors for mortality from SARS-CoV-2 pneumonia include increasing age, coronary heart disease, diabetes mellitus and chronic kidney disease.<sup>7,8</sup> Admission CURB-65 scores do not predict severity or mortality in patients with SARS-CoV-2 pneumonia, due to a rapidly progressing clinical course.<sup>7</sup> However, lymphopenia, eosinopenia and elevated acute phase proteins are predictors of increased disease severity.<sup>7,9,10</sup>

It appears that development of ‘cytokine storm’ in patients with SARS-CoV-2 pneumonia is associated with progression to ARDS, however, the cytopathic effects of the viral pneumonia may be just as



important.<sup>9 11 12</sup> Histological analysis of postmortem lung tissue from SARS-CoV-2 pneumonia patients has shown diffuse alveolar damage (DAD).<sup>13 14</sup> The presence of DAD has previously been used to identify a subphenotype of ARDS with higher mortality.<sup>15 16</sup> These findings suggest that a similar pathological process occurs in patients with ARDS with and without SARS-CoV-2.

Our objective was to determine whether patients with SARS-CoV-2 ARDS are clinically distinct, therefore, requiring alternative management strategies, compared with other patients with ARDS.<sup>17</sup> This retrospective study provides clinical characterisation of ARDS patients with and without SARS-CoV-2 admitted to a single-centre ICU.

## METHODS

This is a single-centre, observational, retrospective study from the ICU of the Queen Elizabeth Hospital Birmingham, UK. All data were routinely collected on the hospital's electronic patient records. Only data that were obtained as part of routine clinical care were collected for this study. All data were anonymised and entered by the Local Clinical Care Team, without linkage to any patient identifiers, in accordance with national and local guidance.

Two ICU cohorts of patients were analysed: SARS-CoV-2 pneumonia patients admitted between 11 March and 21 April 2020 (online supplemental figure 1) and all patients with community-acquired pneumonia (CAP) from bacterial or viral infection who developed ARDS between 1 January 2017 and 1 November 2019 (online supplemental figure 2). Patients who developed hospital-acquired pneumonia (HAP: defined as onset >48 hours after hospital admission) were excluded. This was to identify a more relevant, directly comparable control group, in which infection was acquired in the community, and pneumonia was present at hospital admission. The causative organisms and clinical course of CAP and HAP also differ significantly. Patients with ARDS secondary to others causes were also excluded. The sample sizes were determined pragmatically, to include all SARS-CoV-2 pneumonia patients admitted to the ICU within the first 6 weeks of the pandemic. The sample size of the CAP-ARDS control group included all such patients within the 3 years preceding the pandemic, since all these patients would have their hospital records within a rapidly accessible electronic system, and would have received protocolised management similar to that received by the SARS-CoV-2 ARDS patients.

As patients were from the same institution, their management prior to ICU admission and on ICU were broadly similar following local evidence-based protocols and national guidelines<sup>5</sup> with respect to interventions that affect outcome including low tidal volume ventilation and prone positioning (online supplemental table 1). High frequency oscillatory ventilation was only used as a rescue therapy in patients with refractory severe respiratory failure who were not accepted by an extracorporeal

membrane oxygenation centre, and were managed as per previously published algorithms.<sup>18</sup> All patients were intubated, sedated and mechanically ventilated with positive pressure ventilation. Baseline demographic, comorbidities, laboratory investigations, physiological parameters and severity scores (Acute Physiology And Chronic Health Evaluation II [APACHE II], Sequential Organ Failure Assessment [SOFA] and Murray Lung Injury) were collected at ICU admission. Sequential physiological and laboratory parameters were collected for 7 days whilst on ICU. Sequential data are not available for all patients due to deaths of 15 SARS-CoV-2 and 5 CAP-ARDS patients within 1 week.

Statistical analysis was performed using GraphPad Prism version 8.0. Data distributions were non-parametric and are presented as median with IQR for continuous variables and number (percentage) for categorical variables. Differences between patient groups were analysed using Mann-Whitney-U test for continuous data and Fisher's exact test for categorical data. Two-sided tests were used for all comparisons with  $p < 0.05$  considered statistically significant.

## RESULTS

A total of 111 patients with SARS-CoV-2 ARDS and 29 patients with CAP-ARDS met the inclusion criteria (table 1). Many patients ( $n=33$ ) screened for CAP-ARDS were excluded, as pneumonia had developed >48 hours after hospital admission. Patient demographic details are shown in table 1, with both groups being broadly similar except for ethnic background. A greater proportion of SARS-CoV-2 patients were of Asian/Asian British ethnicity ( $p=0.002$ ), and a lower proportion were of White ethnicity ( $p=0.012$ ), compared with CAP-ARDS patients

On ICU admission, SARS-CoV-2 patients had significantly lower APACHE-II and SOFA scores than CAP-ARDS patients (see table 1:  $p < 0.0001$ ). SOFA scores remained lower in SARS-CoV-2 patients for 7 days following ICU admission (figure 1A).

SARS-CoV-2 patients had lower circulating leukocytes, neutrophils and monocytes ( $p < 0.0001$  for all) than CAP-ARDS patients on ICU admission. Leucocytes and neutrophil counts remained lower in SARS-CoV-2 patients for 3 days following ICU admission, whereas monocyte counts remained lower for 6 days (figure 1B–D). Albumin was lower ( $p=0.003$ ) while CRP ( $p=0.016$ ) and platelet count ( $p=0.029$ ) were higher at ICU admission in SARS-CoV-2 patients. Differences in CRP and albumin between patient groups increased with duration of ICU stay (figure 1E,F). There was no difference in lymphocytes, eosinophils, bilirubin or creatinine between groups on ICU admission.

Positive end-expiratory pressure (PEEP) was higher ( $p=0.003$ ) and tidal volumes were lower ( $p=0.006$ ) in SARS-CoV-2 patients on ICU admission. However, there was no difference in other ventilator parameters between groups on ICU admission, including driving

**Table 1** Demographics, laboratory and physiological characteristics of SARS-CoV-2 ARDS and CAP-ARDS patients on admission to ICU

	SARS-CoV-2 ARDS (n=111)	CAP-ARDS (n=29)	P value
<b>Demographics</b>			
Age at admission (years)	56 (47–63)	55 (41–59)	0.315*
Gender, male (n, %)	84 (75.7%)	19 (65.5%)	0.358†
Body mass index	29 (27–34)	29 (26–33)	0.403*
<b>Ethnicity</b>			
White	54 (48.6%)	22 (75.8%)	<b>0.012†</b>
Asian/Asian British	34 (30.6%)	1 (3.4%)	<b>0.002†</b>
Black/African/Caribbean	9 (8.1%)	0 (0%)	0.204†
Mixed/multiple	3 (2.7%)	1 (3.4%)	0.999†
Other	10 (9.0%)	5 (17.2%)	0.308†
<b>Comorbidities</b>			
None	30 (27.0%)	10 (34.5%)	0.490†
Hypertension	44 (39.6%)	9 (31.0%)	0.520†
Obesity	55 (49.5%)	12 (41.4%)	0.532†
Ischaemic heart disease	6 (5.4%)	1 (3.4%)	>0.999†
Diabetes	33 (29.7%)	4 (13.8%)	0.100†
Asthma/COPD	12 (10.8%)	4 (13.8%)	0.743†
Stroke/TIA	3 (2.7%)	1 (3.4%)	0.999†
Chronic kidney disease	9 (8.1%)	1 (3.4%)	0.688†
Cancer	7 (6.3%)	3 (10.3%)	0.432†
<b>Severity scoring</b>			
APACHE II	14 (12–18)	18 (16–24)	<b>0.0002*</b>
SOFA Score	8 (7–10)	12 (9–14)	<b>&lt;0.0001*</b>
Murray Lung Injury Score	2.75 (2.5–3.0)	2.75 (2.33–3.00)	0.645*
<b>Laboratory parameters on ICU admission</b>			
White cell count (x10 <sup>9</sup> /L)	9.0 (5.9–12.6)	14.6 (10.6–22.9)	<b>&lt;0.0001*</b>
Neutrophils (x10 <sup>9</sup> /L)	6.9 (4.5–10.2)	12.7 (9.0–21.0)	<b>&lt;0.0001*</b>
Lymphocyte (x10 <sup>9</sup> /L)	0.88 (0.57–1.20)	0.7 (0.5–1.2)	0.327*
Monocytes (x10 <sup>9</sup> /L)	0.43 (0.29–0.65)	0.9 (0.6–1.3)	<b>&lt;0.0001*</b>
Eosinophils (x10 <sup>9</sup> /L)	0 (0–0.03)	0 (0–0.1)	0.277*
CRP (mg/L)	172 (113–241)	91 (40–235)	<b>0.016*</b>
Platelets (10 <sup>9</sup> /L)	224 (174–305)	191 (111–294)	<b>0.029*</b>
Creatinine (μmol/L)	77 (64–111)	87 (67–178)	0.260*
Bilirubin (μmol/L)	12 (9–20)	18 (8–45)	0.141*
Albumin (g/L)	27 (24–32)	31 (27–35)	<b>0.003*</b>
<b>Ventilator parameters on ICU admission</b>			
Ppeak (cmH <sub>2</sub> O)	27 (24–30)	28 (24–30)	0.578*
PEEP (cmH <sub>2</sub> O)	10 (8–12)	8 (6–10)	<b>0.003*</b>
Driving pressure (cmH <sub>2</sub> O)	16 (14–19)	19 (14–22)	0.178*
Tidal volume (mL/kg)	5.11 (4.60–5.89)	5.98 (4.87–6.96)	<b>0.013*</b>
Pulmonary compliance (mL/cmH <sub>2</sub> O)	28 (24–34)	25 (22–34)	0.471*
FiO <sub>2</sub> (%)	70 (60–86)	80 (60–100)	0.149*
<b>ICU outcomes</b>			
Hospital mortality	40 (36.0%)	12 (41.4%)	0.668†
Time to death from ICU admission (days)	11 (8–18)	11 (7–17)	0.874*
ICU LoS (days)	17 (10–24)	13 (9–24)	0.344*

Continued



Table 1 Continued

	SARS-CoV-2 ARDS (n=111)	CAP-ARDS (n=29)	P value
ARDS (PaO <sub>2</sub> / FiO <sub>2</sub> ratio kPa)			
Mild (>26.6–40)	6 (5.4%)	2 (6.9%)	0.670†
Moderate (>13.3 ≤26.6)	58 (52.3%)	15 (51.7%)	0.999†
Severe (≤13.3)	47 (42.3%)	12 (41.4%)	0.999†
Day 1 PaO <sub>2</sub> / FiO <sub>2</sub> ratio (kPa)	15 (12–17)	15 (11–17)	0.895*
Duration of mechanical ventilation (days)	15 (9–20)	9 (3–17)	<b>0.012*</b>
Maximum norepinephrine dose on day 1 of ICU admission (µg/kg/min)	0.067 (0.015–0.120)	0.490 (0–0.623)	<b>0.016*</b>
Need for RRT	46 (41.4%)	11 (37.9%)	0.833†
Need for tracheostomy	55 (49.5%)	16 (55.2%)	0.678†

Data are n (%) or median (IQR). Tidal volume calculated using predicted body weight.

\*Represents p-values from a Mann-Whitney U test.

†Represents p-values from a Fisher's exact test.

APACHE II, Acute Physiology And Chronic Health Evaluation II; ARDS, acute respiratory distress syndrome; CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; FiO<sub>2</sub>, fraction of inspired oxygen; ICU, intensive care unit; LoS, length of stay; PaO<sub>2</sub>, partial pressure of oxygen; PEEP, positive end-expiratory pressure; RRT, renal replacement therapy; SOFA, Sequential Organ Failure Assessment.

pressure, peak inspiratory pressure, pulmonary compliance, fraction of inspired oxygen and PaO<sub>2</sub> / FiO<sub>2</sub> ratio. SARS-CoV-2 patients required a lower dose of vasopressors on ICU admission (p=0.016).

SARS-CoV-2 patients required a longer duration of mechanical ventilation compared with CAP-ARDS patients (p=0.010). However, there was no significant difference in other major ICU outcomes between groups, including hospital mortality, ICU length of stay, time to death from ICU admission, development of moderate/severe ARDS, need for renal replacement therapy or need for tracheostomy.

## DISCUSSION

The stark difference between patient numbers indicates that before the emergence of SARS-CoV-2, development of CAP-ARDS was comparatively rare. In keeping with previous findings, our study confirms that SARS-CoV-2 pneumonia seems to disproportionately affect patients from some ethnic minority backgrounds compared with CAP-ARDS.<sup>19</sup>

Patients with SARS-CoV-2 ARDS develop rapid respiratory failure, however other organ functions seem to be initially preserved, with reduced requirement for vasopressors on ICU admission. Severity scores (SOFA, APACHE-II) were higher in the CAP-ARDS group on ICU admission. Similar observations were made in a study comparing patients with SARS-CoV-2 versus H1N1 Influenza,<sup>20</sup> suggesting that SARS-CoV-2 pneumonia initially causes less severe ARDS compared with CAP-ARDS patients who present with mainly bacterial infections or Influenza. However, the increased duration of respiratory failure in SARS-CoV-2 ARDS patients indicates that existing severity scores may not be predictive in this population.


The lower circulating leucocyte and neutrophil count in SARS-CoV-2 ARDS is similar to that observed in a

previous paediatric study comparing pneumonia patients with SARS-CoV-2 vs Influenza A.<sup>21</sup> However, in contrast to this study, we found that CRP was significantly elevated in SARS-CoV-2 patients. Reduced circulating leukocytes in SARS-CoV-2 ARDS patients may indicate a greater migration of neutrophils and monocytes into the alveolar space, impaired leukopoiesis or increased leucocyte clearance. Further studies are required to elucidate the relationship between the observed elevated acute phase proteins and lower circulating leucocytes, which may lead to a greater understanding of SARS-CoV-2 pathogenesis.

While the duration of mechanical ventilation in CAP-ARDS patients was similar to previous ARDS cohorts,<sup>5</sup> the SARS-CoV-2 patients required an increased duration of mechanical ventilation. However, there was no significant difference in most ventilator parameters or other major ICU outcomes (eg, mortality and ICU length of stay) between patient groups. Absolute differences in PEEP and tidal volume between patient groups on ICU admission were small. The requirement for prolonged ventilation support is a key feature of SARS-CoV-2 ARDS, which otherwise causes a clinical syndrome similar to that observed in CAP-ARDS.

Although our CAP-ARDS tracheostomy rates may be considered high by some standards,<sup>5</sup> they are similar to those in other primary ARDS cohorts from European nations,<sup>22</sup> and thus they do not reflect outlying clinical behaviour. Our recent article currently in press ([https://bjanaesthesia.org/article/S0007-0912\(20\)30678-4/full-text](https://bjanaesthesia.org/article/S0007-0912(20)30678-4/full-text)) shows that we did not treat our SARS-CoV-2 patients any differently to our CAP-ARDS patients with regards to tracheostomy decisions, hence there being no significant difference between the groups.

A recent multicentre study by Grasselli *et al* has also compared SARS-CoV-2 ARDS patients with an earlier ARDS patient cohort unrelated to SARS-CoV-2.<sup>23</sup> In contrast to our results, lung compliance was found to



**Figure 1** SOFA score and haematological parameters for SARS-CoV-2 and CAP-ARDS patients over the first 7 days in the ICU. (A) SOFA score. (B): leucocyte count. (C): neutrophil count. (D) monocyte count. (E): CRP. (F): albumin. Data presented as daily median values and IQRs for SARS-CoV-2 ARDS and CAP-ARDS patients. A Mann-Whitney U test was performed at each time point to compare both patient groups: \* $P < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ . ARDS, acute respiratory distress syndrome; CAP, community-acquired pneumonia; ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment Score.

be reduced in SARS-CoV-2 ARDS patients. A subset of patients with SARS-CoV-2 ARDS with low compliance and elevated D-dimers were found to have an increased risk of mortality. Our study may have been underpowered to detect a difference in compliance, as the number of patients included within our study was lower. However, the control group used by Grasselli *et al* was significantly different to ours, with pneumonia being the underlying aetiology in only 57.6% of these patients, compared with 100% in our study.<sup>23</sup>

Several laboratory parameters relevant to SARS-CoV-2 patients including ferritin, lactate dehydrogenase and d-dimer<sup>6 23</sup> were not included in our comparison, because only a small minority of patients in the CAP-ARDS control group had received these investigations. Data regarding the incidence of ARDS in CAP patients were also not available. Despite inclusion of all patients meeting the eligibility criteria at our centre, one of the largest ICU facilities in Europe, the power of our study was low due to the small size of the CAP-ARDS



cohort. There is also a temporal bias in our data, with the SARS-CoV-2 cases being newer. These are significant limitations of our study. Another important limitation of our study is its single-centre observational nature, thus its applicability to a broader range of patients is difficult.

In summary, we show that while the respiratory mechanics of SARS-CoV-2 and CAP-ARDS patients are similar, SARS-CoV-2 patients initially have a lower requirement for vasopressor support, fewer circulating leucocytes and require prolonged ventilation support. We do not recommend changes to the current management of SARS-CoV-2 ARDS based on this study. However, further studies are required to determine whether the dysregulated inflammation observed in SARS-CoV-2 patients contributes to the increased duration of respiratory failure.

#### Author affiliations

<sup>1</sup>Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK

<sup>2</sup>Department of Anaesthesia and Critical Care, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

<sup>3</sup>School of Medical Sciences, The University of Manchester, Manchester, UK

<sup>4</sup>School of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

**Acknowledgements** We thank Sarah Johnson for assistance with data collection.

**Contributors** RYM, MC and JA were responsible for data collection, data analysis and manuscript preparation. CP, AH, RD, EB, LEC and MS were responsible for additional data collection. MB, DP, JP and DRT had overall responsibility for the methodology, data extraction and manuscript preparation.

**Funding** RYM was funded by the MRC (MR/N021185/1).

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** Ethical approval and consent were not required based on Health Research Authority guidance (<https://www.hra.nhs.uk/covid-19-research/guidance-using-patient-data/>). Local governance approval was granted from the audit and quality improvement department.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available on reasonable request. The deidentified participant datasets analysed for this study are available on reasonable request from the corresponding author at: r.mahida@bham.ac.uk.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) licence, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

#### ORCID iDs

Rahul Y Mahida <http://orcid.org/0000-0003-1100-8684>


Dhruv Parekh <http://orcid.org/0000-0002-1508-8362>

## REFERENCES

- Guan W-J, Ni Z-Y, Hu Y, *et al*. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020;382:1708–20.
- ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, *et al*. Acute respiratory distress syndrome: the Berlin definition. *JAMA* 2012;307:2526–33.
- Yang X, Yu Y, Xu J, *et al*. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centred, retrospective, observational study. *Lancet Respir Med* 2020;8:475–81.
- Grasselli G, Zangrillo A, Zanella A, *et al*. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. *JAMA* 2020;323:1574–81.
- Bellani G, Laffey JG, Pham T, *et al*. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. *JAMA* 2016;315:788–800.
- Wu C, Chen X, Cai Y, *et al*. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med* 2020;180:934.
- Du Y, Tu L, Zhu P, *et al*. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. *Am J Respir Crit Care Med* 2020;201:1372–9.
- Posso M, Comas M, Román M, *et al*. Comorbidities and mortality in patients with COVID-19 aged 60 years and older in a university hospital in Spain. *Arch Bronconeumol* 2020;56:756–8.
- Azkur AK, Akdis M, Azkur D, *et al*. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. *Allergy* 2020;75:1564–81.
- Zhou F, Yu T, Du R, *et al*. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395:1054–62.
- Huang C, Wang Y, Li X, *et al*. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497–506.
- Sun X, Wang T, Cai D, *et al*. Cytokine storm intervention in the early stages of COVID-19 pneumonia. *Cytokine Growth Factor Rev* 2020;53:38–42.
- Xu Z, Shi L, Wang Y, *et al*. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020;8:420–2.
- Zhang H, Zhou P, Wei Y, *et al*. Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19. *Ann Intern Med* 2020;172:629–32.
- Cardinal-Fernández P, Bajwa EK, Dominguez-Calvo A, *et al*. The presence of diffuse alveolar damage on open lung biopsy is associated with mortality in patients with acute respiratory distress syndrome: a systematic review and meta-analysis. *Chest* 2016;149:1155–64.
- Roca O, Garcia-de-Acilu M, Soriano-Navarro T, *et al*. Airway alterations and diffuse alveolar damage in acute respiratory distress syndrome: is there any association? *Arch Bronconeumol* 2019;55:3–4.
- Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? *Crit Care* 2020;24:154.
- Lall R, Hamilton P, Young D, *et al*. A randomised controlled trial and cost-effectiveness analysis of high-frequency oscillatory ventilation against conventional artificial ventilation for adults with acute respiratory distress syndrome. The OSCAR (oscillation in ARDS) study. *Health Technol Assess* 2015;19:1–178.
- Aldridge RW, Lewer D, Katikireddi SV, *et al*. Black, Asian and minority ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data. *Wellcome Open Res* 2020;5:88.
- Tang X, Du R-H, Wang R, *et al*. Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1. *Chest* 2020;158:195–205.
- Li Y, Wang H, Wang F, *et al*. Comparison of hospitalized patients with pneumonia caused by COVID-19 and influenza A in children under 5 years. *Int J Infect Dis* 2020;98:80–3.
- Blecha S, Brandl M, Zeman F, *et al*. Tracheostomy in patients with acute respiratory distress syndrome is not related to quality of life, symptoms of psychiatric disorders or return-to-work: the prospective DACAPO cohort study. *Ann Intensive Care* 2020;10:52.
- Grasselli G, Tonetti T, Protti A, *et al*. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. *Lancet Respir Med* 2020. doi:10.1016/S2213-2600(20)30370-2. [Epub ahead of print: 27 Aug 2020].


## Supplemental Information

**Figure S1: CONSORT flowsheet for SARS-CoV-2 ARDS patients**



### Abbreviations

ARDS: Acute Respiratory Distress Syndrome. ECMO: Extra-corporeal membrane oxygenation. ICU = Intensive Care Unit. SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus 2.

**Figure S2: CONSORT flowsheet for CAP-ARDS patients****Abbreviations**

ARDS: Acute Respiratory Distress Syndrome. CAP = Community-Acquired Pneumonia. HAP: Hospital-Acquired Pneumonia. ICU = Intensive Care Unit. SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus 2.

**Table S1: Summary of the protocolised management instituted at our hospital**

Ventilation	Tidal Volume Ppeak/Plateau PaO <sub>2</sub> PaCO <sub>2</sub>	6-8 ml/kg/PBW <30 cmH <sub>2</sub> O Target 8-10 kPa Target to keep pH>7.2
Prone Position		18 hours if FiO <sub>2</sub> ≥0.6
Neuromuscular Blockade		Atracurium infusion
Fluid Balance		Target for neutral balance. Enteral feeds for excluded in fluid balance
Antibiotics		Cessation of routine antibiotics for community acquired pneumonia if SARS-CoV-2 positive
Sedation		Morphine and Midazolam
First-line vasopressor		Noradrenaline
Thromboprophylaxis		<50kg Enoxaparin 40mg daily s/c 50 - 150kg Enoxaparin 40mg twice daily s/c >150kg Enoxaparin 60mg twice daily s/c GFR < 30 mls / min reduce dose by 50%

**Abbreviations**

FiO<sub>2</sub> = Fraction of inspired oxygen. GFR = Glomerular filtration rate. S/C = Subcutaneous.  
PaO<sub>2</sub>/CO<sub>2</sub> = Partial pressure of oxygen / carbon dioxide. PWB = Predicted body weight.